← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
151	151 DELISTED NKGen Biotech, Inc. Common Stock NKGN	–	–	–	–
152	152 Nkarta NKTX $138M	–	–	–	–
153	153 Intellia Therapeutics NTLA $1.59B	–	–	–	–
154	154 OmniAb OABI $688M	–	–	–	–
155	OBX 155 Obsidian Therapeutics OBX $754M	–	–	–	–
156	156 DELISTED Omega Therapeutics, Inc. Common Stock OMGA	–	–	–	–
157	157 DELISTED Singular Genomics Systems, Inc. Common Stock OMIC	–	–	–	–
158	158 DELISTED Orgenesis Inc. Common Stock ORGS	–	–	–	–
159	ORTX 159 DELISTED Orchard Therapeutics plc American Depositary Shares ORTX	–	–	–	–
160	160 Passage Bio PASG $11.6M	–	–	–	–
161	161 PepGen PEPG $175M	–	–	–	–
162	162 PharmaCyte Biotech PMCB $3.84M	–	–	–	–
163	163 Prime Medicine PRME $655M	–	–	–	–
164	164 ProKidney PROK $305M	–	–	–	–
165	165 Personalis PSNL $1.7B	–	–	–	–
166	166 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
167	167 Quantum-Si Incorporated QSI $287M	–	–	–	–
168	RCOR 168 DELISTED Renovacor, Inc. RCOR	–	–	–	–
169	169 Regenxbio RGNX $473M	–	–	–	–
170	170 Atrium Therapeutics RNA $134M	–	–	–	–
171	171 Cartesian Therapeutics RNAC $199M	–	–	–	–
172	RUBY 172 DELISTED Rubius Therapeutics, Inc RUBY	–	–	–	–
173	173 Sana Biotechnology SANA $742M	–	–	–	–
174	SCPS 174 DELISTED Scopus BioPharma Inc. Common Stock SCPS	–	–	–	–
175	SCTX 175 Scribe Therapeutics Inc SCTX $392M	–	–	–	–